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Influenza is a highly contagious virus transmitted by the
respiratory route by inhalation of aerosols as well as by direct
contact with animate or inanimate objects (1). Because it can
spread rapidly in persons in semiclosed or crowded
environments, influenza epidemics have posed major risks to
military populations (2). The impact of influenza on the U.S.
Navy and Marine Corps has been greatly reduced since an
annual immunization program began in 1954 (3,4). This
mandatory program uses the influenza vaccine reformulated
annually by the Vaccine and Related Biological Products
Advisory Committee, Food and Drug Administration (5). The
1995/1996 influenza vaccination program contained A/Texas/
36/91(H1N1), A/Johannesburg/33/94(H3N2), and B/Harbin/
7/94 (6).
Data from the Centers for Disease Control and
Prevention (CDC) indicate that the earliest specimen
collection date for a new variant, A/Wuhan/359/95(H3N2),
was July 1995. The variant was later identified in China
(during August, September, and October 1995), Hong Kong
(October 1995), and Guam (November 1995). During the
winter months of 1996, A/Wuhan/359/95-like viruses were
isolated in Asia, Europe, and North America (7). In February
1996, this virus caused an outbreak onboard a U.S. Navy ship
whose crew had received the 1995-96 influenza vaccine. We
describe the details of this outbreak.
The USS Arkansas is a nuclear-powered, guided missile
cruiser with a complement of >500 men. It was in its home
port of Bremerton, Washington, in January 1996. On
February 1, this cruiser and her sister ship, the USS
California (crew >550 men), departed for a 3-week training
exercise in the waters off southern California. Up to departure
date, the primary contact the two crews had was a shared
dining facility. On February 5, the USS Arkansas contacted
the Navy Environmental and Preventive Medicine Unit in
San Diego, California (NEPMU-5), to report the onset of an
acute febrile respiratory disease in many crew members.
Subsequently, high rates of an incapacitating illness forced
the ship to dock in San Diego, where it remained for 2 days.
The Study
On February 6, >60 crew members reported to the USS
Arkansas medical department with respiratory symptoms;
the 16 most symptomatic patients underwent a complete
medical examination and additional laboratory testing.
Pharyngeal swabs were collected from 50 ill crew members
and submitted for viral culture. After influenza A was
diagnosed, amantadine was flown to the ship and offered, 100
mg twice a day, to unvaccinated persons and those in the first
days of illness. Follow-up surveys and interviews were
conducted in early March after the ship returned from its
training exercises. The crew’s medical, berth, work site, and
immunization records were reviewed.
Case Finding
Several case-finding methods were used in this outbreak.
Initially, cases were identified by the ship’s medical officer
and corpsmen. Their case definition included crew members
seeking medical evaluation with symptoms of fever,
headache, sore throat, and/or cough along with nonspecific
symptoms of fatigue and malaise. NEPMU-5, notified of the
outbreak, sent an epidemiology team to meet the ship. This
team used a symptom-based questionnaire, administered to
the entire crew at the outbreak peak (February 6), to seek
additional cases.
On February 23, the ship returned to Bremerton. A
follow-up investigation then took place, which included
review of sick-call logs and medical department reports,
interviews with select crew members, and a follow-up
questionnaire given to all crew members onboard during the
outbreak. This questionnaire sought to identify the impact of
the outbreak on the ship’s function and the effects of
intervention with amantadine. Those persons who reported a
influenza-like illness on the follow-up questionnaire and had
not yet completed the initial questionnaire were asked to do so.
A person was considered a case if he had a documented
illness consistent with influenza or if he had indicated on the
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initial questionnaire that he had had an influenza-like illness
and associated symptoms in the first 3 weeks of February. A
possible case was a person who had an influenza-like illness
but either did not complete the symptom questionnaire or
completed it before becoming ill.
Fifty pharyngeal swabs collected in viral transport media
were submitted for culture to the virology lab of Green
Hospital at Scripps Clinic in La Jolla, California. Influenza A
virus was identified by immunofluorescent staining of
infected cell cultures with commercially available monoclonal
antibodies. Successfully cultured viruses were forwarded to
San Diego County’s public health department laboratory for
identification of influenza A subtype. The laboratory
forwarded five of these isolates to CDC for antigenic
characterization by hemagglutination-inhibition reactions
with ferret antisera directed against a reference battery of
influenza viral antigens, including currently circulating
strains received from the global World Health Organization
(WHO) influenza network.
Conclusions
A total of 548 Navy crew members and 3 civilians were
onboard February 1-23; 440 crew members (80%) completed
the first questionnaire and 509 (93%) completed the follow-up
questionnaire. All respondents were male, age 18 to 48 years
(mean 26 ± 6 years). Some 523 crew members (95%) had
received the 1995-96 influenza vaccine in December 1995.
Administration had been uniform, and the cold chain was
maintained. The vaccine lot number and administration time
were the same as those used for the crew of the companion
ship, the USS California.
A total of 232 USS Arkansas crew members were
identified with an influenza-like illness during the outbreak
(attack rate = 42%); 158 cases were identified by the medical
department; 74 patients did not seek medical attention but
met case criteria. An additional 63 crew members (11%)
reported having some influenza-like symptoms (probable
cases) but did not meet the definite case criteria. The outbreak
peaked on February 6; the last case was identified on
February 20 (Figure 1). Review of medical logs and interviews
with the medical department and crew of the USS California
revealed that no one aboard that ship had sought medical
attention for influenza-like illness during the training
exercise.
Ill members of the Arkansas crew missed 106 working
days (Figure 2). One patient with severe chest pain as a result
of infection was medically evacuated by helicopter. An
additional 8 work days were lost by probable cases (N = 63).
After influenza A was identified in the crew, amantadine,
100 mg twice a day for 5 days, was offered to all unvaccinated
persons (until the outbreak subsided) and to those in the first
2 days of illness. A total of 59 persons chose to take the
antiviral drug, 49 for therapy and 10 for prophylaxis; 11 of 59
had side effects (insomnia, 4; headache, 4; nausea, 2;
dizziness, 1; and bad dreams, 1). One person discontinued
therapy because of headaches. A total of 28 unvaccinated crew
members were onboard; 11 (61%) of the 18 unvaccinated
persons who did not take amantadine met case criteria for
influenza, but none of 10 unvaccinated persons who took
amantadine prophylaxis had influenza-like symptoms (p-
value <0.03, Fisher’s exact test, 1-tailed).
Interviews and record reviews yielded a possible
explanation for an outbreak’s occurring on the Arkansas but
not on the California, a ship with the same home port and
vaccination schedule and a crew in close proximity until the
day of departure. A sailor returned by plane to Bremerton
from vacation in North Carolina on January 27 and became ill
on January 28. He reported to the USS Arkansas on the day of
departure (February 1). On January 28, a second sailor
visited the first sailor in his home. The second sailor became
ill on January 31 and was immediately placed on the sick list
upon reporting to the Arkansas on February 1. On February 3,
members of the crew who worked and lived in the same parts
of the ship as the second sailor became ill. The outbreak
peaked 3 days later. This correlated with a 3-day incubation
period and efficient transmission. Four of six members of the
investigating team (all Navy personnel vaccinated with the
1995-96 influenza vaccine) had an influenza-like illness that
appeared to respond to amantadine therapy.
Influenza A was isolated from 30 of 50 throat culture
specimens. They were confirmed as influenza A (H3N2) by the
San Diego County Public Health Laboratory. All five isolates
submitted to CDC were antigenically characterized as
A/Wuhan/359/95-like.
This outbreak demonstrates the potential for rapid
spread of influenza A throughout a confined population
despite appropriate vaccination. The efficiency of human-to-
human transmission is emphasized by the fact that there was
no discernible difference in attack rates between various
areas of the ship by the end of the outbreak. Although over
95% of the Arkansas crew were appropriately immunized
with the 1995-96 influenza vaccine, at least 42% became ill Figure 1. Influenza outbreak aboard USS Arkansas, February 1996.
Figure 2. Number of lost workdays during February 1–20, 1996. A
lost workday = day a patient is placed at bed rest with influenza.Dispatches
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with influenza; when definite and probable cases were
included, the attack rate was 54%, for an estimated 46%
efficacy of the 1995-96 influenza vaccine against the Wuhan
strain.
The outbreak reiterates that optimal prevention of
influenza by vaccination depends on the antigenic fit between
the vaccine strain and the infecting virus, which, in turn, is
dependent on the early identification of drift variants. The
identification of the drift variant, A/Wuhan/359/95(H3N2), as
the causative pathogen underscores the need for increasing
the number as well as the capabilities of surveillance
laboratories worldwide to rapidly isolate and identify strains
of currently circulating influenza viruses. In recent years, the
Department of Defense has augmented CDC and WHO
surveillance efforts through establishing a collaborative
network of >30 domestic and international influenza
surveillance sites (8,9). Influenza isolates from this
surveillance have proven valuable in decisions about vaccine
content.
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